CURRICULUM VITAE
Personal Details Surname Papamichael First Name Demetris Address Address (Home) 30, Melina Merkouri St., Engomi 2411, Nicosia, Cyprus (Work) 32 Acropoleos Ave., Strovolos 2006, Nicosia, Cyprus Telephone +35722-847402 (Sec.) +35799426245 (Mob.) e mail: [email protected] Nationality Hellenic Date of Birth 20.05.62 Marital Status Married with one daughter and one son
Education Elenion (Primary School), Nicosia, Cyprus 1968-1974 Pancyprian Gymnasium (Secondary School), 1974-1980 Nicosia, Cyprus Served as second Lieutenant in the Cypriot army 1980-1982 Tank Corps (Conscription service) Medical School - Charing Cross and Westminster, 1982-1987 University of London Qualifications MB BS December 1987
MRCP (UK) 1992 CCST (UK) in Medical Oncology May 1998 FRCP (Lond.) May 2004
Present Director - Department of Medical Oncology Appointments Bank of Cyprus Oncology Centre May 1999 Hon. Associate Professor – St. George’s March 2015 Medical School University of London at the University of Nicosia Campus Bank of Cyprus Oncology Centre
The Bank of Cyprus Oncology Centre was established in 1998 as an autonomous not-for profit specialized Cancer Centre, following an agreement between the Government of Cyprus and the Bank of Cyprus. Operational expenditure is covered by the Government and Capital expenditure by the Bank. It operates as a National referral centre and collaborates with both public and private hospitals for the diagnosis, treatment and management of cancer patients. In its 20 years of operation it has treated more than 38,000 patients. It receives an average of 200 new cancer cases a month, which represents about 75% of the total cancer incidence in Cyprus. It has state of the art facilities including three linear accelerators covering all national referrals for radiotherapy without a waiting list and a Chemotherapy Day Unit administering approximately 85 treatments / day. As the Director of Medical Oncology, I have been involved with the setting up and organization of the Cancer Centre from the outset. The Cancer Centre has achieved international accreditation back in 2007, and following regular reviews is maintained to date. The overall strategy of the Centre includes: attraction, development and retention of high calibre human resources, site specialisation of health professionals at the Centre, multidisciplinary collaboration with health professionals from private and public hospitals and voluntary organisations, operation of systems to assure quality and patient safety and to maintain the organisation on a learning and improving trajectory, undertaking of research and encouragement of health professionals to participate in scientific meetings and to publish, continuing education and training of those working at the Centre and of the collaborating health professionals, keeping abreast of changing technology through investment in new equipment and systems as well as through personal and professional development of all staff, employment of consultant grade medical staff only on salary and on five year revolving contracts which explicitly prohibit private work for personal gain. Prizes/Awards Aylwen Bursary - Awarded by the Joint Research Board / Special Trustees of St. Bartholomew’s Hospital, March 1996 Hans Wyder Fellowship - Awarded by the European Society for Medical Oncology (ESMO), June 1996 Clinical Training Fellowship - Awarded by the Joint Research Board / Special Trustees of St. Bartholomew’s Hospital, May 1997 American Society of Clinical Oncology (ASCO) - Merit Award May 1998
Research activities/portfolio
Clinical Research Over the last fifteen years I have developed a special interest in the treatment of gastrointestinal malignancies. This is reflected in the clinical trial portfolio set out below as well as in my publication record. Participating or have participated in the following clinical trials as a P.I.: 1. MOSAIC – Randomised trial in the adjuvant therapy of colon cancer 2. PETACC-3 – Adjuvant therapy of colon cancer 3. Tirapazamine trial in advanced NSCLC 4. Randomised trial in advanced colorectal cancer – FOCUS – NCRI / Colorectal Cancer Trials Group – UK 5. Neoadjuvant therapy for stage III NSCLC – EORTC-LCG 6. Prophylactic Cranial Irradiation in Extensive SCLC – EORTC-LCG 7. Conventional vs Higher dose Prophylactic Irradiation for Limited SCLC – EORTC/LCG 8. Sequential use of Iressa in patients with metastatic NSCLC responding to first-line chemotherapy – EORTC-LCG 9. FOLFOX+Cetuximab vs FOLFIRI+Cetuximab, a randomized phase II study – CECOG 10. COIN B – NCRN-MRC / UK 11. FOLFIRI+sunitinib vs FOLFIRI+placebo – The “SUN” trial
12. A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for metastatic pancreatic cancer “VANILLA” study.
13. An open-label, randomized, controlled, multi-center, Phase 1/11 trial investigating 2 EMD 525797 doses in combination with cetuximab + irinotecan versus cetuximab + irinotecan alone, as second-line treatment for subjects with k- ras wild type (WT) metastatic colorectal cancer (mCRC). “POSEIDON” trial.
14. A non-interventional follow-up to the MOSAIC study (multicentre international study of Oxaliplatin/5-Fluorouracil/Leucovorin in the adjuvant treatment of colon cancer) up to 10 years and translational research “MOSAIC EXTENSION”(C09-2)
15. A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine with and without IMM-101 in Advanced Pancreatic Cancer (IMM- 101-002) 16. Treatment of patients with KRAS wild type advanced colorectal cancer with 5-fluorouracil (5-FU) or 5-FU plus an Epidermal Growth Factor Receptor inhibitor (cetuximab) based on a Comprehensive Geriatric Assessment. EORTC. 17. Screening Platform of the EORTC for Clinical Trials in Advanced Colorectal cancer “SPECTAcolor” 18. A Prospective, Multicenter, Randomized, Double Blind, Placebo- controlled, 2-Parallel Groups, Phase 3 Study to compare the efficacy and safety of Masitinib in combination with Folfiri (Irinotecan, 5-Fluorouracil and Folinic Acid) to Placebo in combination with Folfiri In second line treatment of patients with Metastatic Colorectal Cancer 19. A Multi-Center Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (MODUL) 20. A-REPEAT - Anti EGFR re-challenge and plasma genotyping of patients with advanced colorectal tumors. Teaching and educational activities - Involved in teaching for the European School of Oncology Courses (ESO). In addition, I have been involved in the organization of 3 ESO Masterclass courses in Cyprus. I am currently part of the ESO Faculty. - Teaching on the postgraduate course of the Hellenic Academy of Oncology, aimed at trainees in Medical Oncology from Greece and Cyprus. - Have been invited to give educational lectures at ESMO, ECCO and ESMO GI meetings on a number of occasions. - Recently, I have acquired the role of a Task Force leader for the International Society of Geriatric Oncology (SIOG), in order to develop guidelines for the management of older patients with colorectal cancer. This has culminated in recommendations that were initially published in 2099 and updated in 2013. - Member of the ESMO metastatic Colorectal Guidelines Group - ESMO faculty member for the Gastro-Intestinal Tumours Group - Member of the ESMO membership Committee - Teaching of Medical Students from St. George’s Hospital / Medical School (London) at the University of Nicosia Campus
Membership of Professional and other Organisations European Society for Medical Oncology (ESMO) The Royal College Of Physicians - United Kingdom (RCP-UK) American Society of Clinical Oncology (ASCO) International Society of Geriatric Oncology (SIOG)
Membership of Research and Educational Organisations National Cancer Research Network - UK – National Colorectal Cancer Trials Group European Organisation for Research and Treatment of Cancer – GI Group International Society For Geriatric Oncology (SIOG)
Publications
Citations: 9100 h-index: 21
1. Joel SP, Ellis P, O’Byrne K, Papamichael D, Hall M, Penson RT, Nicholls SE, O’Donnell C, Constantinou A, Woodhull J, Nicholson M, Smith I, Talbot D, Slevin M L. Therapeutic monitoring of continuous infusion etoposide in small cell lung cancer. J Clin Oncol 14(6):1903-1912, 1996
2. Papamichael D, Andrews T, Owen D, Carter M, Amess J, Lister TA, Rohatiner AZS. Intensive Chemotherapy for Adult Acute Lymphoblastic Leukaemia given with or without granulocyte / macrophage Colony Stimulating Factor. Ann Haematol 73 : 259-263, 1996
3. Papamichael D, Gallagher CJ, Oliver RTD, Johnson PW, Waxman J. Phase II study of Paclitaxel in pre-treated patients with locally advanced / metastatic cancer of the bladder and ureter. Br J Cancer 75: 606-607, 1997 4. J M Foran, J Apostolidis, D Papamichael, A J Norton, J Matthews, J A L Amess, T A Lister, A Z S Rohatiner. High dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Ann Oncol 9 : 865-869, 1998 5. S Joel, K O’Byrne, R Penson, D Papamichael, A Higgins, H Robertshaw, R Rudd, D Talbot, M Slevin. A randomised concentration - controlled, comparison of standard (5 day) vs prolonged (15 day) infusions of etoposide phosphate in small cell lung cancer. Ann Oncol 9 : 1205-1211, 1998 6. M L Slevin, D Papamichael. Is there a standard adjuvant treatment for colon cancer? (Current Controversies in Cancer Section). Eur J Cancer 34: 1652- 1663, 1998 7. D Papamichael, N Amft, M L Slevin, D D’Cruz. 5-Fluorouracil induced Raynaud’s phenomenon. Eur J Cancer 34 (12): 1983, 1998 8. D Papamichael, , M T Seymour, R T Penson, P Wilson, C J Gallagher, G M Besser, M L Slevin. A phase II study of interferon alpha -2a and modulated 5- fluorouracil in patients with advanced neuroendocrine tumours. Eur J Cancer 34: 2133-2134, 1998 9. D Papamichael, A J Norton, J M Foran, C Mulatero J Matthews, J A L Amess, M Bradburn, T A Lister, A Z S Rohatiner. Immunocytoma - A Retrospective Analysis from St. Bartholomew’s Hospital 1972-1996. J Clin Oncol 17:2847-2854, 1999 10. D Papamichael. The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: Current status. The Oncologist 4: 478- 487, 1999 11. Seymour M T, Dent J T, Papamichael D, Creswell H E, Wilson G. Epirubicin, cisplatin and oral UFT (ECU): infusional chemotherapy without the infusion. Ann Oncol 10 : 1329-1333, 1999 12. D Papamichael. The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: Current status. Stem Cells. 2000;18(3):166-75 13. A. de Gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi, J. Cassidy, C. Boni, H. Cortes-Funes, A. Cervantes, G. Freyer, D. Papamichael, N. Le Bail, C. Louvet, D. Hendler, F. de Braud, C. Wilson, F. Morvan, and A. Bonetti Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. J Clin Oncol 16: 2938-2947, 2000 14. C.W.Mularero, R.T.Penson, D.Papamichael, N.H.Gower, M.Evans, R.M.Rudd. A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma. Lung Cancer 31: 67-72, 2001 15. D Papamichael. The prognostic role of angiogenesis in colorectal cancer. Anticancer Res 21:4349-53, 2001 16. Bjorkholm M, Johansson E, Papamichael D, Celsing F, Matthews J, Lister TA, Rohatiner AZ. Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: A two institution study. Semin Oncol 30:226-30, 2003 17. A. Bamias, D. Papamichael, K. Syrigos, N. Pavlidis Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer J Chemotherapy15: 275-81,2003 18. Simon P Joel, Demetris Papamichael, Fiona Richards, Theresa Davis, Vasilis Aslanis, Etienne Chatelut, Kathryn Locke, Maurice L Slevin, Matt T Seymour. Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. Clin Pharmacol Ther 76: 45-54, 2004 19. Fountzilas G, Tolis C, Kalogera-Fountzila A, Karanikiotis C, Bai M, Misailidou D, Samantas E, Athanassiou E, Papamichael D, Tsekeris P, Catodritis N, Nicolaou A, Plataniotis G, Makatsoris T, Papakostas P, Zamboglou N, Daniilidis J. Induction Chemotherapy with Cisplatin, Epirubicin, and Paclitaxel (CEP), Followed by Concomitant Radiotherapy and Weekly Paclitaxel for the Management of Locally Advanced Nasopharyngeal Carcinoma A Hellenic Cooperative Oncology Group Phase II Study. Strahlenther Onkol. 181:223-230, 2005 20. Hadjisavvas A, Papasavva D, Loizidou M, Malas S, Potamitis G, Christodoulou C, Pavlidis G, Papamichael D, Klonis C, Nasioulas G, Anastasiadou V, Kyriakou K. Novel germline mutations in the APC gene of Cypriot patients with familial and sporadic adenomatous polyposis. Clin Genet 69:404-9, 2006 21. Papamichael D. Colon Cancer Adjuvant Therapy: Current Status. CME Journal Gastroenterology, Hepatology & Nutrition 8: 3-10, 2007 22. Charisios Karanikiotis, Michail Daniilidis, Nikolaos Kariotis, Charalambos Bakogiannis, Theophanis Economopoulos, Samuel Murray, Demetris Papamichael, Epaminondas Samantas, Angelos Nicolaou, Lemonia Skoura, Nicolaos Tselis, Nokolaos Zamboglou, George Fountzilas. HLA Class II Alleles and the Presence of Circulating Epstein-Barr Virus DNA in Greek Patients with Nasopharyngeal Carcinoma. Strahlenther Onkol.184:325–31, 2008 23. Evangelia Razis, Evangelos Briasoulis, Eleni Vrettou, Dimosthenis V Skarlos, Dimitrios Papamichael, Ioannis Kostopoulos, Epaminontas Samantas, Ioannis Xanthakis, Mattheos Bobos, Eleni Galanidi, Maria Bai, Ioanna Gikonti, Alona Koukouma, Georgia Kafiri, Pavlos Papakostas, Konstantine T Kalogeras, Paris Kosmidis and George Fountzilas . Potential value of PTEN in predicting cetuximab response in colorectal cancer. An exploratory study. BMC Cancer; 8:234, 2008 24. D Papamichael. Challenges in treating older cancer patients: colon cancer. Ann Oncol 19 (suppl 7): vii104-vii108, 2008 25. D. Papamichael; R. Audisio; J.-C. Horiot; B. Glimelius; J. Sastre; E. Mitry; E. Van Cutsem; M. Gosney; C.-H. Kohne; M. Aapro Treatment of the elderly colorectal cancer patient: SIOG expert recommendations Ann Oncol 20:5- 16, 2009 26. Fortunato Ciardiello, Sabine Tejpar, Demetris Papamichael. Implications of k-ras mutation status for the treatment of metastatic colorectal cancer. Target Oncol 4:311-322, 2009 27. A.G. Pallis , D. Papamichael , R. Audisio , M. Peeters , G. Folprecht , D. Lacombe , E. Van Cutsem. EORTC Elderly Task Force experts’ opinion for the treatment of colon cancer in older patients. Cancer Treat Rev 36:83-90, 2010 28. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC. World J Gastroenterol 16: 3133-43, 2010 29. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. Lancet Oncol. 11:753-62, 2010 30. Intramedullary spinal cord metastasis in a patient with colon cancer: a case report. Vassiliou V, Papamichael D, Polyviou P, Koukouma A, Andreopoulos D. J Gastrointest Cancer 43: 131-5, 2012 31. Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer. Kalofonos HP, Papakostas P, Makatsoris T, Papamichael D, Vourli G, Xanthakis I, Aravantinos G, Papadimitriou C, Pentheroudakis G, Varthalitis I, Samelis G, Syrigos KN, Xiros N, Stavropoulos M, Kosmidis P, Christodoulou C, Linardou H, Skondra M, Pectasides D, Economopoulos T, Fountzilas G. Anticancer Res. 30:4325-33, 2010 32. Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. Hawkes E, Okines AF, Papamichael D, Rao S, Ashley S, Charalambous H, Koukouma A, Chau I, Cunningham D. Eur J Cancer. 47:1146-51, 2011 33. Isolated right atrial metastasis of malignant melanoma mimicking a myxoma. Kontozis L, Soteriou M, Papamichael D, Economides C, Bagdades E, Christou C, Oxynou C. Hellenic J Cardiol. 52:281-4, 2011 34. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Gaafar RM, Surmont VF, Scagliotti GV, Van Klaveren RJ, Papamichael D, Welch JJ, Hasan B, Torri V, van Meerbeeck JP; EORTC Lung Cancer Group and the Italian Lung Cancer Project. Eur J Cancer. 47:2331-40, 2011 35. Barrett's esophagus: treatment or observation of a major precursor factor of esophageal cancer? Kountourakis P, Papademetriou K, Ardavanis A, Papamichael D. J BUON. 16:425-30, 2011 36. Targeted agents: review of toxicity in the elderly metastatic colorectal cancer patients. Kyriakou F, Kountourakis P, Papamichael D. Target Oncol. 6:245-51, 2011 37. Presacral Extramedullary Hematopoiesis in a Patient with Rectal Adenocarcinoma: Report of a Case and Literature Review. Vassiliou V, Papamichael D, Lutz S, Eracleous E, Kountourakis P, Polyviou P, Michaelides I, Shoukris M, Andreopoulos D. J Gastrointest Cancer. 43 Suppl 1:S131-5, 2012 38. Adjuvant chemoradiotherapy (CRT) for high-risk gastric cancer (GC) patients: single-center experience using infusional 5-fluorouracil (5FU) and radiotherapy (RT). Papadimitriou K, Vassiliou V, Kountourakis P, Polyviou P, Andreopoulos D, Papamichael D. Med Oncol. 29:2716-7, 2012 39. Treatment of colorectal cancer in older patients. Audisio RA, Papamichael D. Nat Rev Gastroenterol Hepatol. 9:716-25, 2012 40. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G. BMC Cancer 13:13-49, 2013 41. Adjuvant therapy for resectable pancreatic adenocarcinoma: review of the current treatment approaches and future directions. Antoniou G, Kountourakis P, Papadimitriou K, Vassiliou V, Papamichael D. Cancer Treat Rev. 40:78-85, 2014 42. The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. Strimpakos A, Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Andreadou A, Sgouros J, Zizi-Sermpetzoglou A, Kominea A, Televantou D, Razis E, Galani E, Pectasides D, Tejpar S, Syrigos K, Fountzilas G. Clin Colorectal Cancer. 12:267- 274.e2, 2013 43. A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG). Pentheroudakis G, Kotoula V, Fountzilas E, Kouvatseas G, Basdanis G, Xanthakis I, Makatsoris T, Charalambous E, Papamichael D, Samantas E, Papakostas P, Bafaloukos D, Razis E, Christodoulou C, Varthalitis I, Pavlidis N, Fountzilas G. BMC Cancer. 14:111, 2014 44. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. Razis E, Pentheroudakis G, Rigakos G, Bobos M, Kouvatseas G, Tzaida O, Makatsoris T, Papakostas P, Bai M, Goussia A, Samantas E, Papamichael D, Romanidou O, Efstratiou I, Tsolaki E, Psyrri A, De Roock W, Bafaloukos D, Klouvas G, Tejpar S, Kalogeras KT, Pectasides D, Fountzilas G. J Cancer Res Clin Oncol. 140:737-48, 2014 45. Treatment of older patients with colorectal cancer: a perspective review. Kordatou Z, Kountourakis P, Papamichael D. Ther Adv Med Oncol. 6:128-40, 2014 46. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Geva R, Vecchione L, Kalogeras KT, Jensen BV, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S. Gut. 64:921-8, 2015 47. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller D, Köhne CH, Rostoft S, Lemmens V, Mitry E, Rutten H, Sargent D, Sastre J, Seymour M, Starling N, Van Cutsem E, Aapro M. Ann Oncol. 26:463-76, 2015 48. Voice disorders induced by bevacizumab administration in an ovarian cancer patient: an underestimated and rare toxicity. Kountourakis P, Antoniou G, Papadimitriou K, Vassiliou V, Syrigos D, Philippou M, Papamichael D. Hematol Oncol Stem Cell Ther. 7:123-4, 2014 49. The mutational spectrum of Lynch syndrome in Cyprus. Loizidou MA, Neophytou I, Papamichael D, Kountourakis P, Vassiliou V, Marcou Y, Kakouri E, Ioannidis G, Philippou C, Spanou E, Tanteles GA, Anastasiadou V, Hadjisavvas A, Kyriacou K. PLoS One. 9:e105501, 2014 50. Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward. Papadimitriou K, Antoniou G, Rolfo C, Russo A, Bronte G, Vassiliou V, Papamichael D, Peeters M, Kountourakis P. Gastroenterol Res Pract. 2015:650846 51. Oral single-agent chemotherapy in older patients with solid tumours: A position paper from the International Society of Geriatric Oncology (SIOG). Biganzoli L, Lichtman S, Michel JP, Papamichael D, Quoix E, Walko C, Aapro M. Eur J Cancer. 51:2491-500, 2015 52. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont A. J Clin Oncol. 33:4176-87, 2015 53. Adjuvant chemotherapy for colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO. Kountourakis P, Souglakos J, Gouvas N, Androulakis N, Athanasiadis A, Boukovinas I, Christodoulou C, Chrysou E, Dervenis C, Emmanouilidis C, Georgiou P, Karachaliou N, Katopodi O, Makatsoris T, Papakostas P, Pentheroudakis G, Pilpilidis I, Sgouros J, Tekkis P, Triantopoulou C, Tzardi M, Vassiliou V, Vini L, Xynogalos S, Xynos E, Ziras N, Papamichael D. Ann Gastroenterol. 29:18-23, 2016 54. Clinical Practice guidelines for the surgical management of colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO. Xynos E, Gouvas N, Triantopoulou C, Tekkis P, Vini L, Tzardi M, Boukovinas I, Androulakis N, Athanasiadis A, Christodoulou C, Chrysou E, Dervenis C, Emmanouilidis C, Georgiou P, Katopodi O, Kountourakis P, Makatsoris T, Papakostas P, Papamichael D, Pentheroudakis G, Pilpilidis I, Sgouros J, Vassiliou V, Xynogalos S, Ziras N, Karachaliou N, Zoras O, Agalianos C, Souglakos J; [the Executive Team on behalf of the Hellenic Society of Medical Oncology (HeSMO)]. Ann Gastroenterol. 29:3-17, 2016
55. Clinical practice guidelines for the surgical treatment of rectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO). Xynos E, Tekkis P, Gouvas N, Vini L, Chrysou E, Tzardi M, Vassiliou V, Boukovinas I, Agalianos C, Androulakis N, Athanasiadis A, Christodoulou C, Dervenis C, Emmanouilidis C, Georgiou P, Katopodi O, Kountourakis P, Makatsoris T, Papakostas P, Papamichael D, Pechlivanides G, Pentheroudakis G, Pilpilidis I, Sgouros J, Triantopoulou C, Xynogalos S, Karachaliou N, Ziras N, Zoras O, Souglakos J; [the Executive Team on behalf of the Hellenic Society of Medical Oncologists (HeSMO)]. Ann Gastroenterol. 29:103-26, 2016
56. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. Ann Oncol. 27:1386-422, 2016
57. Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. Papamichael D, Renfro LA, Matthaiou C, Yothers G, Saltz L, Guthrie KA, Van Cutsem E, Schmoll HJ, Labianca R, André T, O'Connell M, Alberts SR, Haller DG, Kountourakis P, Sargent DJ; Adjuvant Colon Cancer Endpoints (ACCENT) Group. J Geriatr Oncol. 7:422-429, 2016 58. Randomised, open-label, phase II study of gemcitabine with and without IMM- 101 for advanced pancreatic cancer. Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Martín AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS. Br J Cancer. 115:789-96, 2016
59. Clinical practice guidelines for the management of metastatic colorectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO). Dervenis C, Xynos E, Sotiropoulos G, Gouvas N, Boukovinas I, Agalianos C, Androulakis N, Athanasiadis A, Christodoulou C, Chrysou E, Emmanouilidis C, Georgiou P, Karachaliou N, Katopodi O, Kountourakis P, Kyriazanos I, Makatsoris T, Papakostas P, Papamichael D, Pechlivanides G, Pentheroudakis G, Pilpilidis I, Sgouros J, Tekkis P, Triantopoulou C, Tzardi M, Vassiliou V, Vini L, Xynogalos S, Ziras N, Souglakos J. Ann Gastroenterol. 29:390-416, 2016
60. BRCA1 and BRCA2 mutation testing in Cyprus; a population based study. Loizidou MA, Hadjisavvas A, Pirpa P, Spanou E, Delikurt T, Tanteles GA, Daniel M, Kountourakis P, Malas S, Ioannidis G, Zouvani I, Kakouri E, Papamichael D, Marcou Y, Anastasiadou V, Kyriacou K. Clin Genet. 91:611- 615, 2017
61. Geriatric factors and outcomes in metastatic colorectal cancer. Papamichael D, Aapro M. Eur J Cancer.74:96-97, 2017
62. Chromogranin A as a valid marker in oncology: Clinical application or false hopes? Gkolfinopoulos S, Tsapakidis K, Papadimitriou K, Papamichael D, Kountourakis P. World J Methodol. 7:9-15, 2017
63. Management of gastric cancer in older adults. Matthaiou C, Papamichael D. J Geriatr Oncol. 8:403-406, 2017
64. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. Ruff P, Van Cutsem E, Lakomy R, Prausova J, van Hazel GA, Moiseyenko VM, Soussan-Lazard K, Dochy E, Magherini E, Macarulla T, Papamichael D. J Geriatr Oncol. 9:32-39, 2018
65. Leptomeningeal metastases originated from esophagogastric junction/gastric cancer: A brief report of two cases. Kountourakis P, Papamichael D, Haralambous H, Michael M, Nakos G, Lazaridou S, Fotiou E, Vassiliou V, Andreopoulos D. World J Gastrointest Oncol. 10:56-61, 2018
66. Identifying patients who may benefit from oxaliplatin-containing perioperative chemo(radio)therapy for rectal cancer. Papamichael D, Glynne-Jones R. Ann Oncol. 29:1616-1618, 2018
67. Advances in molecular, genetic and immune signatures of gastric cancer: Are we ready to apply them in our patients' decision making? Gkolfinopoulos S, Papamichael D, Papadimitriou K, Papanastasopoulos P, Vassiliou V, Kountourakis P. World J Gastrointest Oncol. 10:172-183, 2018
68. Optimal management of localized rectal cancer in older patients. Bujko K, Glynne-Jones R, Papamichael D, Rutten HJT. J Geriatr Oncol. 9:696-704, 2018
69. Personalized management of elderly patients with rectal cancer: Expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer. Montroni I, Ugolini G, Saur NM, Spinelli A, Rostoft S, Millan M, Wolthuis A, Daniels IR, Hompes R, Penna M, Fürst A, Papamichael D, Desai AM, Cascinu S, Gèrard JP, Myint AS, Lemmens VEPP, Berho M, Lawler M, De Liguori Carino N, Potenti F, Nanni O, Altini M, Beets G, Rutten H, Winchester D, Wexner SD, Audisio RA. Eur J Surg Oncol. 44:1685-1702, 2018
Book Chapters
1. D Papamichael, K N Syrigos. Novel Therapeutic Strategies For Bladder Cancer. In: Bladder Cancer – Biology, Diagnosis and Management. 1999, Eds K N Syrigos, D Skinner.
2. A Adamou, D Papamichael. Chemotherapy for Advanced Breast Cancer. In: Gynaecological Oncology. 2001, Eds D Pectasides, M A Demopoulos.
3. Demetris Papamichael and Ricardo Audisio. Colon Cancer. In: Cancer and Aging Handbook. 2012, Eds Keith Bellizzi, Margot Ann Gosney
Previous Appointments
Consultant Medical Oncologist Bank of Cyprus Oncology Centre 01.08.98-01.05.99 Dept. of Medical Oncology
Clinical Research Fellow St. Bartholomew’s Hospital, London 01.03.96-30.07.98 Medical Oncology Barry Reed Oncology Laboratory Consultant / Supervisor: Dr M L Slevin
Specialist Registrar St. Bartholomew’s Hospital, London 01.12.92-29.02.96 Medical Oncology Consultants: Professor T A Lister, Dr A Z S Rohatiner, Professor R T D Oliver, Dr M L Slevin, Dr C J Gallagher, Dr R M Rudd
Senior House Officer St. Bartholomew’s Hospital, London 01.02.92-31.07.92 Neurology Consultant: Dr G Gawler
Brook General Hospital, Woolwich, London 01.04.91-30.09.91 Cardiology Consultants: Dr R J Wainwright Dr A Fenech
Royal Marsden Hospital, Sutton, Surrey 01.05.90-31.01.91 Medical Oncology (Junior Lecturer) Consultants: Professor T J Mc Elwain Dr D Cunningham
Medway Hospital, Gillingham, Kent 01.02.89-31.01.90 Medical Rotation - Internal Medicine (1 year) Consultants: Dr R C Day Dr G Smith-Laing Dr P L Williams Dr B K Sharma
House Officer Medway Hospital, Gillingham, Kent 01.08.88-31.01.89 Internal Medicine/Cardiology/Chest Medicine Consultants: Dr I M O’Brien Dr D Thompson
Charing Cross Hospital, London 01.02.88-31.07.88 General Surgery Consultant: Mr T G Allen-Mersh